一名接受英夫利昔单抗治疗难治性溃疡性结肠炎的患者出现白癜风。
Vitiligo in a patient receiving infliximab for refractory ulcerative colitis.
作者信息
Ismail Waleed A, Al-Enzy Saleh A, Alsurayei Saqer A, Ismail Ali E
机构信息
Department of Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
出版信息
Arab J Gastroenterol. 2011 Jun;12(2):109-11. doi: 10.1016/j.ajg.2011.03.001. Epub 2011 May 4.
Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha (TNFα) and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis (UC). We report a case of vitiligo following infliximab administration in a patient with refractory UC. The case serves as a reminder of adverse cutaneous reactions induced by TNFα-antagonist therapy.
英夫利昔单抗是一种嵌合单克隆抗体，可抑制肿瘤坏死因子α（TNFα）的促炎活性，它是治疗中重度溃疡性结肠炎（UC）的主要生物制剂。我们报告了1例难治性UC患者在使用英夫利昔单抗后发生白癜风的病例。该病例提醒人们注意TNFα拮抗剂治疗引起的皮肤不良反应。
Zotero 插件